甲状腺癌血清标志物临床应用专家共识(2017 版)

2018-01-30 中国抗癌协会甲状腺癌专业委员会 中国肿瘤临床.2018,45(1):7-13.

甲状腺癌的临床发病率近年来逐年上升,其风险评估和临床管理方法也随之发生变化并不断完善。国内不同医疗机构在甲状腺癌的临床诊疗模式和疾病管理存在较大差异,尤其是甲状腺癌血清标志物的临床应用方面。针对于此,中国抗癌协会甲状腺癌专业委员会组织编写《甲状腺癌血清标志物临床应用专家共识》,旨在帮助和推进各相关临床机构及专业人员在甲状腺癌临床诊疗和长期管理方面的规范化建设,合理应用甲状腺癌血清标志物,科学辅助甲

中文标题:

甲状腺癌血清标志物临床应用专家共识(2017 版)

发布日期:

2018-01-30

简要介绍:

甲状腺癌的临床发病率近年来逐年上升,其风险评估和临床管理方法也随之发生变化并不断完善。国内不同医疗机构在甲状腺癌的临床诊疗模式和疾病管理存在较大差异,尤其是甲状腺癌血清标志物的临床应用方面。针对于此,中国抗癌协会甲状腺癌专业委员会组织编写《甲状腺癌血清标志物临床应用专家共识》,旨在帮助和推进各相关临床机构及专业人员在甲状腺癌临床诊疗和长期管理方面的规范化建设,合理应用甲状腺癌血清标志物,科学辅助甲状腺癌术前、术后的临床诊断和评估。本专家共识就甲状腺癌血清标志物检测共提出14条推荐条款,鉴于目前国内外可供参考的资料尤其是前瞻性资料有限,疏漏在所难免,也希望专业人士多提宝贵意见,以便今后定期修订。

 

拓展指南:甲状腺癌相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=甲状腺癌血清标志物临床应用专家共识(2017 版))] GetToolGuiderByIdResponse(projectId=1, id=415781c001566a6f, title=甲状腺癌血清标志物临床应用专家共识(2017 版), enTitle=, guiderFrom=中国肿瘤临床.2018,45(1):7-13., authorId=null, author=, summary=甲状腺癌的临床发病率近年来逐年上升,其风险评估和临床管理方法也随之发生变化并不断完善。国内不同医疗机构在甲状腺癌的临床诊疗模式和疾病管理存在较大差异,尤其是甲状腺癌血清标志物的临床应用方面。针对于此,中国抗癌协会甲状腺癌专业委员会组织编写《甲状腺癌血清标志物临床应用专家共识》,旨在帮助和推进各相关临床机构及专业人员在甲状腺癌临床诊疗和长期管理方面的规范化建设,合理应用甲状腺癌血清标志物,科学辅助甲, cover=, journalId=null, articlesId=null, associationId=1612, associationName=中国抗癌协会甲状腺癌专业委员会, associationIntro=, copyright=0, guiderPublishedTime=Tue Jan 30 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>甲状腺癌的临床发病率近年来逐年上升,其风险评估和临床管理方法也随之发生变化并不断完善。国内不同医疗机构在甲状腺癌的临床诊疗模式和疾病管理存在较大差异,尤其是甲状腺癌血清标志物的临床应用方面。针对于此,中国抗癌协会甲状腺癌专业委员会组织编写《甲状腺癌血清标志物临床应用专家共识》,旨在帮助和推进各相关临床机构及专业人员在甲状腺癌临床诊疗和长期管理方面的规范化建设,合理应用甲状腺癌血清标志物,科学辅助甲状腺癌术前、术后的临床诊断和评估。本专家共识就甲状腺癌血清标志物检测共提出14条推荐条款,鉴于目前国内外可供参考的资料尤其是前瞻性资料有限,疏漏在所难免,也希望专业人士多提宝贵意见,以便今后定期修订。 </P> <P> </P>拓展指南:<STRONG>与<FONT color=red>甲状腺癌</FONT>相关指南:</STRONG><BR> <UL> <LI><A title=美国甲状腺学会《儿童甲状腺结节与分化型甲状腺癌诊治指南》解读 target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=d82a91c001a9e934">美国甲状腺学会《儿童甲状腺结节与分化型甲状腺癌诊治指南》解读</A> <LI><A title=NCCN临床实践指南:甲状腺癌(2017.V1) target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=9e1b41c001ae6141">NCCN临床实践指南:甲状腺癌(2017.V1)</A> <LI><A title="2017 法国分化型甲状腺癌放射性碘治疗,分子成像和血清标志物检查指南" target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=5c6921c001a49559">2017 法国分化型甲状腺癌放射性碘治疗,分子成像和血清标志物检查指南</A> <LI><A title=成人甲状腺结节与分化型甲状腺癌诊治指南(2015年美国甲状腺协会)解读 target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=fad5e1c001a481ab">成人甲状腺结节与分化型甲状腺癌诊治指南(2015年美国甲状腺协会)解读</A> <LI><A title=NCCN临床实践指南:甲状腺癌(2017.V2) target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=c1e341c001a38358">NCCN临床实践指南:甲状腺癌(2017.V2)</A> 更多信息请点击:<A target=_blank href="http://www.medsci.cn/guideline/list.do?q=%E7%94%B2%E7%8A%B6%E8%85%BA%E7%99%8C">有关甲状腺癌更多指南</A></LI></UL>, tagList=[TagDto(tagId=865, tagName=甲状腺癌), TagDto(tagId=4694, tagName=血清标志物)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=30, categoryName=耳鼻咽喉科, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8070, appHits=864, showAppHits=7, pcHits=5930, showPcHits=2065, likes=141, shares=32, comments=8, approvalStatus=1, publishedTime=Sun Mar 11 22:19:28 CST 2018, publishedTimeString=2018-01-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Mar 11 22:19:28 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 16:33:52 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=甲状腺癌血清标志物临床应用专家共识(2017 版))])
甲状腺癌血清标志物临床应用专家共识(2017 版)
下载请点击:
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=295462, encodeId=36f829546212, content=厉害了我的哥, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Mar 12 08:18:13 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295417, encodeId=c68f29541e66, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Mar 12 07:12:44 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295365, encodeId=755a295365ca, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Mon Mar 12 06:10:18 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295327, encodeId=3f5829532e39, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Mar 12 00:05:43 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295306, encodeId=4010295306dc, content=甲状腺癌的临床发病率近年来逐年上升.其风险评估和临床管理方法也随之发生变化并不断完善.国内不同医疗机构在甲状腺癌的临床诊疗模式和疾病管理存在较大差异.尤其是甲状腺癌血清标志物的临床应用方面., beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Mar 11 23:07:42 CST 2018, time=2018-03-11, status=1, ipAttribution=)]
    2018-03-12 飛歌

    厉害了我的哥

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=295462, encodeId=36f829546212, content=厉害了我的哥, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Mar 12 08:18:13 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295417, encodeId=c68f29541e66, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Mar 12 07:12:44 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295365, encodeId=755a295365ca, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Mon Mar 12 06:10:18 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295327, encodeId=3f5829532e39, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Mar 12 00:05:43 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295306, encodeId=4010295306dc, content=甲状腺癌的临床发病率近年来逐年上升.其风险评估和临床管理方法也随之发生变化并不断完善.国内不同医疗机构在甲状腺癌的临床诊疗模式和疾病管理存在较大差异.尤其是甲状腺癌血清标志物的临床应用方面., beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Mar 11 23:07:42 CST 2018, time=2018-03-11, status=1, ipAttribution=)]
    2018-03-12 131****1460

    学习了受益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=295462, encodeId=36f829546212, content=厉害了我的哥, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Mar 12 08:18:13 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295417, encodeId=c68f29541e66, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Mar 12 07:12:44 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295365, encodeId=755a295365ca, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Mon Mar 12 06:10:18 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295327, encodeId=3f5829532e39, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Mar 12 00:05:43 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295306, encodeId=4010295306dc, content=甲状腺癌的临床发病率近年来逐年上升.其风险评估和临床管理方法也随之发生变化并不断完善.国内不同医疗机构在甲状腺癌的临床诊疗模式和疾病管理存在较大差异.尤其是甲状腺癌血清标志物的临床应用方面., beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Mar 11 23:07:42 CST 2018, time=2018-03-11, status=1, ipAttribution=)]
    2018-03-12 121832a9m88暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=295462, encodeId=36f829546212, content=厉害了我的哥, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Mar 12 08:18:13 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295417, encodeId=c68f29541e66, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Mar 12 07:12:44 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295365, encodeId=755a295365ca, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Mon Mar 12 06:10:18 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295327, encodeId=3f5829532e39, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Mar 12 00:05:43 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295306, encodeId=4010295306dc, content=甲状腺癌的临床发病率近年来逐年上升.其风险评估和临床管理方法也随之发生变化并不断完善.国内不同医疗机构在甲状腺癌的临床诊疗模式和疾病管理存在较大差异.尤其是甲状腺癌血清标志物的临床应用方面., beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Mar 11 23:07:42 CST 2018, time=2018-03-11, status=1, ipAttribution=)]
    2018-03-12 明月清辉

    谢谢分享.学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=295462, encodeId=36f829546212, content=厉害了我的哥, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Mar 12 08:18:13 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295417, encodeId=c68f29541e66, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Mar 12 07:12:44 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295365, encodeId=755a295365ca, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Mon Mar 12 06:10:18 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295327, encodeId=3f5829532e39, content=谢谢分享.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Mar 12 00:05:43 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295306, encodeId=4010295306dc, content=甲状腺癌的临床发病率近年来逐年上升.其风险评估和临床管理方法也随之发生变化并不断完善.国内不同医疗机构在甲状腺癌的临床诊疗模式和疾病管理存在较大差异.尤其是甲状腺癌血清标志物的临床应用方面., beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Mar 11 23:07:42 CST 2018, time=2018-03-11, status=1, ipAttribution=)]
    2018-03-11 有备才能无患

    甲状腺癌的临床发病率近年来逐年上升.其风险评估和临床管理方法也随之发生变化并不断完善.国内不同医疗机构在甲状腺癌的临床诊疗模式和疾病管理存在较大差异.尤其是甲状腺癌血清标志物的临床应用方面.

    0